/

Empresas

OS

No verificado

OS Therapies

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaOncologíaSalud

28 Comunicados de prensa

Ver todos los comunicados de prensa

03/07/2025

Ciencia

Higiene alimentaria

Medicina - Varios

Sanidad

Biotecnología

Farmacéutica

Salud

Oncología

Industria

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Fuente

Editor

1.00

0

30/06/2025

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Eventos

Industria

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

Fuente

Editor

1.00

0

24/06/2025

Oncología

Higiene alimentaria

Salud

Medicina - Varios

Farmacéutica

Biotecnología

Eventos

Industria

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

Fuente

Editor

1.00

0

15/05/2025

Industria

Ciencia

Sanidad

Familia

Farmacéutica

Oncología

Ir de compras

Venta al público/Minorista

Biotecnología

Salud

Animales

OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

Fuente

Editor

1.00

0

07/05/2025

Industria

Ciencia

Veterinaria

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040

Fuente

Editor

1.00

0

02/05/2025

Industria

Web y redes sociales

Mundo del espectáculo

Cine

Familia

Oncología

Ir de compras

Biotecnología

Salud

Animales

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

Fuente

Editor

1.00

0

22/04/2025

Industria

Cine

Biotecnología

Higiene alimentaria

Salud

Web y redes sociales

Farmacéutica

Mundo del espectáculo

Oncología

Ciencia

Medicina - Varios

OS Therapies FDA Meeting Request Granted

Fuente

Editor

1.00

0

10/04/2025

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

Fuente

Editor

1.00

0

09/04/2025

Mercado de valores

Industria

Ciencia

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

Fuente

Editor

1.00

0

07/04/2025

Industria

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Higiene alimentaria

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0